Can a systemic steroidogenic downshift cause low morning cortisol plus low testosterone and low estradiol/progesterone?

All steroid hormones are chemically derived from cholesterol and share a fundamental biosynthetic pathway, making a simultaneous decline in multiple hormone classes mechanistically possible. In the context of endocrine aging—specifically for a female in her mid-50s—the concurrent presentation of low morning cortisol, low testosterone, and low estradiol/progesterone represents a plausible clinical picture of systemic steroidogenic downshift.

Mechanistic basis of steroidogenesis

The synthesis of all steroid hormones relies on a conserved biochemical cascade that originates from a single primary precursor: cholesterol.

• Universal precursor: Within the mitochondria, the enzyme CYP11A1 converts cholesterol into pregnenolone, which serves as the "master" precursor for all steroid classes.
• Shared intermediates: Progesterone is synthesized directly from pregnenolone. It serves both as a final hormone and as a critical metabolic intermediate for the production of cortisol (via the glucocorticoid pathway) and sex steroids like testosterone and estradiol (via the androgen/estrogen pathway).
• Pathway divergence: The 17,20-lyase activity of the CYP17A1 enzyme acts as a key regulatory checkpoint, directing precursors away from the mineralocorticoid/glucocorticoid pathways and toward sex steroid production.

Clinical evidence for systemic downshift

The concept of a broader downshift reflects the interconnected nature of the Hypothalamic-Pituitary-Adrenal (HPA) and Hypothalamic-Pituitary-Gonadal (HPG) axes, particularly during the menopausal transition.

• Adrenal and ovarian involution: Evidence from menopausal cohorts indicates that adrenal cortex aging can occur alongside ovarian decline. Research shows cortisol production can decrease by 1.2–2.0 times in some individuals experiencing menopausal syndrome, appearing alongside significant drops in estradiol and progesterone.
• Cross-axis impact: Stress-induced or age-related HPA axis dysregulation often correlates with suppressed HPG axis function. High levels of follicle-stimulating hormone (FSH) and parathyroid hormone (PTH) have been linked to broader endocrine shifts that impact bone density and metabolic health.
• Variability in cortisol: While a downshift is plausible, it is not universal. Some studies observe that cortisol levels may actually increase or fluctuate during the menopausal transition due to the loss of estrogen’s inhibitory effect on the HPA axis.

Bottom line

The claim is biologically supported and clinically plausible. Because all steroid hormones share cholesterol and pregnenolone as mandatory precursors, a systemic downshift in steroidogenesis can manifest as concurrent low levels of morning cortisol, testosterone, and progesterone/estradiol. This profile is frequently observed during the menopausal transition as a result of synchronized adrenal and ovarian involution.